Michael J. Fox Foundation backs Rhythm's drug candidate

09/11/2013 | American City Business Journals

The Michael J. Fox Foundation for Parkinson's Research awarded Rhythm Pharmaceuticals a $1.4 million grant to support a midstage study of ghrelin agonist RM-131, its drug candidate for refractory constipation, which affects many Parkinson's disease patients. "As we continue our work to advance RM-131 in the clinic, we are excited to join with The Michael J. Fox Foundation to address this important unmet need in Parkinson’s disease," Rhythm CEO Keith Gottesdiener said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA